Dual GIP/GLP-1 Receptor Agonism

Two incretin hormones, two receptors

Incretins are hormones released from intestinal endocrine cells in response to food intake that potentiate glucose-stimulated insulin secretion. The two principal incretins are glucagon-like peptide-1 (GLP-1, secreted by L cells in the distal small intestine and colon) and glucose-dependent insulinotropic polypeptide (GIP, secreted by K cells in the proximal small intestine). Together, GLP-1 and GIP account for approximately 50% to 70% of the insulin response to oral glucose — the so-called 'incretin effect'¹.

Both receptors are class B GPCRs sharing similar architecture (large N-terminal extracellular domain, 7TM core). GLP-1R is expressed broadly (pancreas, brain, GI tract, cardiovascular system); GIPR is expressed in pancreas, adipose tissue, bone, and selected brain regions. The two receptors share approximately 41% amino acid sequence identity.

Why GIP monotherapy failed

Decades of work attempted to develop GIP-based therapies for type 2 diabetes. Native GIP and GIP receptor agonists demonstrated robust insulin secretion in healthy individuals but disappointingly modest effects in patients with type 2 diabetes — a phenomenon called the 'GIP defect of T2D.' The defect involves receptor downregulation and possibly altered receptor coupling in diabetic islets.

Additionally, GIP has been associated with adipocyte lipid storage and weight gain — opposite to GLP-1's anorectic effects. Pre-clinical work showed that GIP receptor antagonism (rather than agonism) might be the beneficial strategy for obesity. This created decades of confusion about whether GIP should be activated or blocked in metabolic disease.

The breakthrough came from observation that in the context of weight loss and GLP-1 co-activation, GIP receptor activation produced complementary rather than antagonistic effects. The mechanism is incompletely understood; current hypotheses include weight-loss-induced restoration of GIP responsiveness, complementary effects on adipose tissue, and altered receptor cross-talk².

Tirzepatide structure and binding

Tirzepatide is a 39-amino-acid peptide engineered de novo to bind both GLP-1R and GIPR. The molecule combines GIP-like and GLP-1-like sequences with strategic substitutions optimized for dual binding. A C20 fatty diacid linker confers albumin binding and a 5-day half-life.

Binding affinity is approximately 5-fold lower for GLP-1R than native GLP-1, and similar to native GIP at GIPR. The 'imbalanced' affinity (greater at GIPR than at GLP-1R, relative to native ligands) is hypothesized to be intentional, producing a different signal balance than either native peptide alone³.

Clinical evidence: SURPASS and SURMOUNT programs

The SURPASS program tested tirzepatide in type 2 diabetes. SURPASS-1 (monotherapy) showed mean HbA1c reductions of 1.87% to 2.07% across doses. SURPASS-2 (head-to-head versus semaglutide 1 mg) showed greater HbA1c reduction and greater weight loss with all tirzepatide doses⁴. SURPASS-3 added comparison with insulin degludec; SURPASS-4 with insulin glargine; both showed tirzepatide superiority on weight and glycemic measures. SURPASS-5 evaluated tirzepatide as add-on to insulin.

The SURMOUNT program extended evaluation to obesity without diabetes. SURMOUNT-1 (the pivotal obesity trial) showed mean weight loss of 15.0% to 20.9% across doses versus 3.1% with placebo at 72 weeks⁵. SURMOUNT-2 (obesity with T2D), SURMOUNT-3 (intensive lifestyle lead-in), and SURMOUNT-4 (maintenance) all supported the obesity indication.

The SURMOUNT-OSA trial demonstrated significant improvement in obstructive sleep apnea with tirzepatide, leading to an FDA approval for OSA in adults with obesity in 2024.

Mechanism of the additional weight loss

Cross-trial comparison suggests tirzepatide 15 mg produces approximately 6 percentage points more weight loss than semaglutide 2.4 mg. Why?

Hypothesis 1 — additive appetite effects: GIPR activation in the central nervous system may contribute to anorectic signaling complementary to GLP-1R.

Hypothesis 2 — improved nutrient handling: GIPR activation on adipose tissue may shift glucose uptake from adipose toward muscle, reducing fat storage.

Hypothesis 3 — reduced nausea allowing higher functional dose: by reducing GLP-1R-mediated nausea (via the GIP component's possible anti-nausea effect), tirzepatide may achieve effective receptor activation at doses tolerated by more patients.

Hypothesis 4 — sustained efficacy: the dual-receptor signal may produce less tachyphylaxis than GLP-1R activation alone, sustaining weight loss over longer periods.

Each hypothesis has supporting evidence; none has been conclusively isolated. The mechanism is likely multifactorial⁶.

Next generation: triple agonism (retatrutide)

Retatrutide adds glucagon receptor activation to the GIP/GLP-1 dual mechanism. Glucagon receptor activation increases energy expenditure (thermogenesis, fatty acid oxidation), complementing GLP-1's effects on appetite suppression and gastric emptying. The combination produced 24.2% mean weight loss in a Phase 2 obesity trial at the 12 mg dose over 48 weeks — the largest weight loss reported for any incretin-class agent to date&sup7;.

Retatrutide is in Phase 3 development (TRIUMPH program). Submission to the FDA is expected in 2027. If the Phase 2 weight-loss magnitude is confirmed in Phase 3 with acceptable safety, retatrutide would offer weight-loss outcomes approaching those of bariatric surgery (typically 25% to 35% sustained loss).

Beyond triple agonism, the field is exploring further receptor combinations (amylin agonism with cagrilintide-semaglutide combinations, glucagon-like peptide-2 agonism, FGF-21 mimetics) and biased agonism approaches that may produce greater efficacy with reduced side effects.

Related editorial coverage

• GLP-1 receptor pharmacology — comprehensive
• Tirzepatide peptide profile
• Retatrutide peptide profile
• SURMOUNT-1 trial deep-dive

Frequently asked questions

What is the difference between a single agonist and a dual agonist?

A single agonist activates one receptor. Semaglutide is a single agonist (GLP-1 receptor only). A dual agonist activates two receptors simultaneously. Tirzepatide is a dual agonist (GLP-1 and GIP receptors). The dual mechanism produces greater weight loss and glycemic control than single agonism, presumably through complementary effects on appetite, energy expenditure, and metabolic regulation.

Is GIP responsible for the extra weight loss with tirzepatide?

Partially. Tirzepatide's added GIP receptor activation contributes to its greater efficacy versus GLP-1 monotherapy, but the mechanism is multifactorial. Hypotheses include complementary appetite suppression, improved nutrient handling, reduced nausea allowing higher functional dose, and sustained efficacy with less tachyphylaxis.

Why didn't GIP work alone for diabetes treatment?

Native GIP has impaired insulinotropic effects in patients with type 2 diabetes — the 'GIP defect of T2D.' GIP also promotes adipocyte lipid storage. The combination of these factors led decades of GIP-based development to fail until tirzepatide demonstrated that GIP co-activation with GLP-1 produces complementary rather than counterproductive effects.

What is retatrutide and how is it different from tirzepatide?

Retatrutide is an investigational triple agonist that activates the GLP-1, GIP, and glucagon receptors. The added glucagon receptor activation increases energy expenditure complementary to appetite suppression from GLP-1. Phase 2 trial weight loss was 24.2% at 12 mg/week over 48 weeks — substantially greater than tirzepatide. Retatrutide is expected to seek FDA approval around 2027&sup7;.